Presentation: Enabling Scalable Cell Engineering Using Maxcyte Electroporation Platform
This presentation was given during the Association of Biomolecular Resources Facilities Meeting (ABRF) March 2022.
Abstract:
MaxCyte is a U.S.-based global company leveraging its proprietary electroporation technology to accelerate the discovery, development, manufacturing and commercialization of next-generation medicines. During this presentation, we will explore how MaxCyte’s unique electroporation technology enables highly efficient, scalable engineering of cell lines and primary cells for a range of applications, including transient protein production, cell line development, and cell therapy manufacturing. We will showcase how our partners utilize the MaxCyte platform to shorten timelines, reduce cost, and de-risk cell engineering processes from concept to commercialization.